CRISPR (CRSP) Rated Overweight on Gene Editing Growth

CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the stocks that could 10x over the next 10 years. Piper Sandler boosted its price target for CRISPR Therapeutics AG (NASDAQ:CRSP) to $110 from $105 on March 17, retaining an Overweight rating in response to the company’s convertible note issuance. CRISPR Therapeutics AG (NASDAQ:CRSP) raised $600 million in convertible notes due in March 2031, convertible at $76.56 per share and with an effective interest rate of 1.73%. The company also allowed initial purchasers to pick up an extra $50 million in notes, with the transaction set to finalize in March of this year.

Moreover, CRISPR Therapeutics AG (NASDAQ:CRSP) plans to disclose Phase I data on zugo-cel in autoimmune diseases and B-cell lymphoma in the latter half of 2026. The company also plans to begin Phase I research on CTX340 in the first half of 2026 and CTX460 in mid-2026.

Meanwhile, in the second half of 2026, CRISPR Therapeutics AG (NASDAQ:CRSP) will provide Phase Ib data on CTX310 and proof-of-concept Phase II data on CTX611 in patients undergoing total knee replacement.

CRISPR Therapeutics AG (NASDAQ:CRSP) is a leader in gene-editing technology, using its proprietary gene sequencing platform to develop precise treatments for diseases requiring DNA modification.

While we acknowledge the risk and potential of CRSP as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CRSP and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.